Search results
Results from the WOW.Com Content Network
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013. [5] In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. [6] In June 2015, the company acquired Cord Blood Registry for $700 million. [7] In 2014, AMAG acquired Lumara Health, formerly KV ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?